Procaps Group Past Earnings Performance
Past criteria checks 1/6
Procaps Group's earnings have been declining at an average annual rate of -13.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 4.8% per year. Procaps Group's return on equity is 135.8%, and it has net margins of 12.6%.
Key information
-13.2%
Earnings growth rate
-13.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -4.8% |
| Return on equity | 135.8% |
| Net Margin | 12.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That Procaps Group (NASDAQ:PROC) Is Using Debt Extensively
Mar 28
Is Procaps Group S.A. (NASDAQ:PROC) Worth US$3.7 Based On Its Intrinsic Value?
Feb 02Calculating The Intrinsic Value Of Procaps Group S.A. (NASDAQ:PROC)
Feb 01Procaps Group reports Q2 results
Aug 30Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)
Jan 10Revenue & Expenses Breakdown
How Procaps Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 414 | 52 | 179 | 0 |
| 30 Jun 23 | 406 | 67 | 174 | 0 |
| 31 Mar 23 | 408 | 33 | 183 | 0 |
| 31 Dec 22 | 410 | 43 | 185 | 0 |
| 30 Sep 22 | 435 | 60 | 175 | 0 |
| 30 Jun 22 | 431 | -73 | 168 | 0 |
| 31 Mar 22 | 418 | -67 | 156 | 0 |
| 31 Dec 21 | 410 | -101 | 151 | 0 |
| 30 Sep 21 | 401 | -119 | 157 | 0 |
| 30 Jun 21 | 374 | -9 | 147 | 0 |
| 31 Mar 21 | 342 | -18 | 137 | 0 |
| 31 Dec 20 | 331 | -10 | 128 | 0 |
| 01 Jan 20 | 325 | -17 | 145 | 0 |
Quality Earnings: PROC has a large one-off gain of $40.5M impacting its last 12 months of financial results to 30th September, 2023.
Growing Profit Margin: PROC's current net profit margins (12.6%) are lower than last year (13.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PROC has become profitable over the past 5 years.
Accelerating Growth: PROC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PROC had negative earnings growth (-13.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (54.6%).
Return on Equity
High ROE: Whilst PROC's Return on Equity (135.77%) is outstanding, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 00:28 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Procaps Group S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Samuel Campos Alves | BTG Pactual |